Holen Sie sich die Stockscreener-App
8.40
0.24%
-0.02
Handel nachbörslich:
8.40
Schlusskurs vom Vortag:
$8.42
Offen:
$8.42
24-Stunden-Volumen:
140.65K
Relative Volume:
0.48
Marktkapitalisierung:
$280.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.20M
KGV:
-5.3664
EPS:
-1.5653
Netto-Cashflow:
$-43.65M
1W Leistung:
-10.54%
1M Leistung:
-25.13%
6M Leistung:
-60.43%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.30
$8.96
1-Wochen-Bereich:
$8.30
$9.80
52-Wochen-Spanne:
$8.30
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Vergleichen Sie MBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
8.40 | 280.71M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences Inc Reports Q4 2024 Net Loss of $15.6 Million, S - GuruFocus.com
MBX Biosciences reports Q4 EPS (47c), consensus (59c) - MSN
MBX Biosciences stock jumps 5% on clinical trial progress - Investing.com India
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
MBX Biosciences Announces Enrollment Completion in Phase 2 Avail™ Trial of Canvuparatide; Phase 2 Trials for MBX 1416 and IND Filing for MBX 4291 Expected in 2025 - Nasdaq
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide - Yahoo Finance
Rhumbline Advisers Purchases New Stake in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences Announces Additions to Leadership Team - GlobeNewswire
MBX Biosciences strengthens leadership team with new SVPs By Investing.com - Investing.com Canada
MBX Biosciences Announces Additions To Leadership Team -March 05, 2025 at 08:53 am EST - Marketscreener.com
MBX Biosciences strengthens leadership team with new SVPs - Investing.com India
MBX Biosciences, Inc.’s Lock-Up Period Will Expire on March 12th (NYSE:MBX) - Defense World
MBX Biosciences Completes Enrollment In Phase 2 Avail Trial Of Canvuparatide For HP - Nasdaq
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - The Manila Times
MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109 - TipRanks
Can This Overenrolled Clinical Trial Transform Hypoparathyroidism Treatment? - StockTitan
Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Acquires 47,502 Shares of Stock - MarketBeat
Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Purchases 143,170 Shares of Stock - MarketBeat
Major Stakeholders Double Down on MBX Biosciences with Substantial Stock Purchases! - TipRanks
OrbiMed Advisors makes $2 million investment in MBX Biosciences By Investing.com - Investing.com India
Mbx biosciences director Carl Gordon purchases over $2 million in stock - Investing.com
Mbx biosciences director Carl Gordon purchases over $2 million in stock By Investing.com - Investing.com South Africa
MBX Biosciences to Participate in March Investor Conferences - GlobeNewswire
Inside MBX Biosciences' Strategic Move: Key Healthcare Conference Presentations Revealed - StockTitan
BIO CEO 2025: The quest for next-gen obesity meds - BioWorld Online
Reviewing Maravai LifeSciences (NASDAQ:MRVI) and MBX Biosciences (NYSE:MBX) - Defense World
MBX Biosciences Inc (MBX) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Analytical Overview: MBX Biosciences Inc (MBX)’s Ratios Tell a Financial Story - The Dwinnex
Investing in MBX Biosciences Inc (MBX) Is Getting More Attractive - Knox Daily
Maravai LifeSciences (NASDAQ:MRVI) & MBX Biosciences (NYSE:MBX) Critical Comparison - Armenian Reporter
MBX Biosciences, Inc. (NYSE:MBX) CEO Purchases $534,500.00 in Stock - MarketBeat
The Future of MBX Biosciences Inc: Analyzing MBX - The InvestChronicle
12 Health Care Stocks Moving In Thursday's Pre-Market SessionInvivyd (NASDAQ:IVVD) - Benzinga
MBX Biosciences Director Makes Bold Stock Move - TipRanks
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
MBX Biosciences to Participate in Upcoming February Investor Conferences - The Manila Times
MBX Biosciences CEO to Present at Three Major Healthcare Investor Conferences in February - StockTitan
16,400 Shares in MBX Biosciences, Inc. (NYSE:MBX) Purchased by Barclays PLC - Defense World
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket - Benzinga
Geode Capital Management LLC Invests $579,000 in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Long-acting MBX 2109 may offer more convenient symptom relief - Hypoparathyroidism News
Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia - Yahoo Finance
MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action - AOL
MBX Biosciences (NYSE:MBX) Shares Gap DownTime to Sell? - MarketBeat
MBX 1416 shows promise in Phase 1 trial for hypoglycemia treatment - Investing.com India
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):